Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Neuronetics (STIM) Other Operating Expenses (2017 - 2025)

Neuronetics (STIM) has disclosed Other Operating Expenses for 9 consecutive years, with $11.7 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses rose 166.24% to $11.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $47.5 million through Dec 2025, up 163.03% year-over-year, with the annual reading at $15.9 million for FY2025, 121.18% up from the prior year.
  • Other Operating Expenses for Q4 2025 was $11.7 million at Neuronetics, down from $11.8 million in the prior quarter.
  • The five-year high for Other Operating Expenses was $13.7 million in Q2 2022, with the low at -$22.2 million in Q3 2024.
  • Average Other Operating Expenses over 5 years is $5.4 million, with a median of $11.7 million recorded in 2022.
  • The sharpest move saw Other Operating Expenses tumbled 282.48% in 2024, then skyrocketed 167.78% in 2025.
  • Over 5 years, Other Operating Expenses stood at $10.3 million in 2021, then increased by 16.38% to $12.0 million in 2022, then fell by 2.41% to $11.7 million in 2023, then plummeted by 251.31% to -$17.7 million in 2024, then soared by 166.24% to $11.7 million in 2025.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at $11.7 million, $11.8 million, and $11.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.